OMass Therapeutics
OMass Therapeutics Raises $310M Series C for Small-Molecule Therapeutics
OMass Therapeutics announced $310M in Series C financing on October 15, 2026. OMass Therapeutics raised an oversubscribed $310 million Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings to advance its small molecule pipeline in endocrinology and immunology.
Round details
The financing includes backing from Bain Capital Life Sciences, Forbion, Novo Holdings, Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, Syncona, Oxford Science Enterprises. The company did not publish a valuation with the announcement.
- Round: Series C
- Capital announced: $310M
- Headquarters: Oxford, UK
How the company plans to use the capital
OMass said the proceeds will advance its lead MC2 receptor antagonist OMS1620 through Phase 2 development in congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. The financing will also support generation of initial clinical data for its SLC15A4 inhibitor program in lupus and other diseases.
Why this matters for GTM teams
The oversubscribed round was co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, and each of the company’s existing investors also participated.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: OMass Therapeutics Series C announcement.
Company Info
Investors (8)
Share
Related Reports
Infisical Raises $40M Series B for AI Agent Security Infrastructure
Infisical raised a $40 million Series B at a $600 million valuation, led by Elad Gil, to expand security infrastructure for AI agents.
Vera Health Raises $28.5M Series A for Clinical AI Search
Vera Health raised a $28.5 million Series A led by Threshold Ventures to further develop its clinical evidence infrastructure and expand into additional healthcare markets.
Omnichat Raises US$10M Series A for Agentic Customer Experience Platform
Omnichat raised a US$10 million Series A led by Openspace Capital to scale its agentic AI platform, deepen R&D on Omni AI Agents and expand globally.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free